WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase . In Vitro WKYMVM-NH2 TFA (10-1000 nM; 24 hours) induces Caco-2 cells proliferation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Caco-2 cells (the intestinal epithelial cells) Concentration: 0 nM, 10 nM, 100 nM, 1000 nM Incubation Time: 24 hours Result: Induced cell proliferation. In Vivo WKYMVM-NH2 TFA (8 mg/kg; six times; for 5 days) ameliorates DSS-induced ulcerative colitis. WKYMVM-NH2 TFA affects cytokine (IL-17, IFN-γ, IL-6, IL-1β and TNF-α) profiles in the DSS colitis model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Six-week-old C57BL/6 mice, DSS modelDosage: 8 mg/kg Administration: Subcutaneously injected, six subcutaneous administrations at 12-h intervals, for 5 days Result: Attenuated the DSS-induced increase in the bleeding score and the stool score. Form:Solid